Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of Evenamide, a glutamate release modulator, as an add-on treatment for adults with treatment-resistant schizophrenia TRS. The study aims to compare the effects of Evenamide 15 mg twice daily with a placebo, focusing on its efficacy, safety, and tolerability in patients who do not respond adequately to their current stable antipsychotic medications. This is a Phase III, randomized, double-blind, placebo-controlled trial involving approximately 400 participants. Participants will be randomly assigned to receive either Evenamide capsules 15 mg twice daily or matching placebo capsules twice daily, alongside their standard antipsychotic treatment, for a total of 12 weeks. The treatment period is designed to assess the added benefit of Evenamide compared to placebo when used as an add-on therapy. Both groups will follow the same dosing schedule, and neither participants nor researchers will know which treatment is being administered until the study is complete. Throughout the 12-week treatment, participants will undergo evaluations including the Positive and Negative Syndrome Scale PANSS, Clinical Global Impression scores, and assessments of personal and social performance and quality of life. Safety will be closely monitored by tracking adverse events during treatment and for 30 days after the treatment period ends. Participants adherence to prescribed antipsychotic treatment will be observed, and the total study duration includes the treatment phase plus a safety follow-up period.
Actively Recruiting
Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.
Actively Recruiting
Researchers are evaluating REGN7508, an experimental drug, compared to Acetylsalicylic Acid ASA to prevent symptomatic Venous Thromboembolism VTE and related conditions after elective, unilateral total knee replacement surgery in adults. This Phase 3 study aims to understand the drugs effectiveness and safety, including potential side effects and immune responses. Participants will be randomly assigned to receive either REGN7508 with a placebo or ASA with a placebo, following the study protocol. The study uses a double-blinded, parallel design where treatments are administered according to protocol after surgery. Monitoring includes tracking drug levels in the blood and checking for antibodies against REGN7508. During the study, participants will undergo assessments for symptomatic VTE, deep vein thrombosis, pulmonary embolism, bleeding events, and adverse reactions up to 90 days after surgery. The primary measurement is the incidence of symptomatic VTE or death within 30 days. Researchers will also collect safety and drug concentration data to evaluate the drugs effects comprehensively throughout the follow-up period.